Danaparoid as the prophylaxis for hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation in childhood hematological malignancy

Pediatric Blood and Cancer

Volumn 55, Issue 6, 2010, Pages 1118-1125

  Sakaguchi, Hirotoshi ^a   Watanabe, Nobuhiro ^b   Muramatsu, Hideki ^c   Doisaki, Sayoko ^b   Yoshida, Nao ^a   Matsumoto, Kimikazu ^a   Kato, Koji ^a  

^a JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Dalteparin; Danaparoid; Regimen related toxicity; Veno occlusive disease

Indexed keywords

ALPHA TOCOPHEROL; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; BUSULFAN; CYCLOSPORIN A; DALTEPARIN; DANAPAROID; FLUDARABINE; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN; MELPHALAN; METHOTREXATE; TACROLIMUS; URSODEOXYCHOLIC ACID;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL INFECTION; BLEEDING; CANCER RADIOTHERAPY; CHILD; CHILDHOOD CANCER; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; INFANT; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MYCOSIS; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHONDROITIN SULFATES; DERMATAN SULFATE; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPARITIN SULFATE; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INFANT; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 77958521968     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22645     Document Type: Article

References (32)

1. Jacobs P, Miller JL, Uys CJ, et al. Fatal veno-occlusive disease of the liver after chemotherapy, whole-body irradiation and bone marrow transplantation for refractory acute leukaemia. S Afr Med J 1979; 55: 5-10.
2. Jones RJ, Lee KS, Beschorner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-783.
3. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
4. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85: 3005-3020.
5. Richardson PG, Elias AD, Krishnan A, et al. Treatment of severe veno-occlusive disease with defibrotide: Compassionate use results in response without significant toxicity in a high-risk population. Blood 1998; 92: 737-744.
6. Chopra R, Eaton JD, Grassi A, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: Results of the European compassionate-use study. Br J Hematol 2000; 111: 1122-1129.
7. Corbacioglu S, Greil J, Peters C, et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): A retrospective multicenter study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant 2004; 33: 189-195.
8. Kami M, Mori S, Tanikawa S, et al. Risk factors for hepatic veno-occlusive disease after bone marrow transplantation: Retrospective analysis of 137 cases at a single institution. Bone Marrow Transplant 1997; 20: 397-402.
9. Carreras E, Bertz H, Arcese W, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: A prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998; 92: 3599-3604.
10. Hasegawa S, Horibe K, Kawabe T, et al. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with haematologic malignancies: Incidence, onset time and risk factors. Bone Marrow Transplant 1998; 22: 1191-1197.
11. Reiss U, Cowan M, McMillan A, et al. Hepatic venoocclusive disease in blood and bone marrow transplantation in children and young adults: Incidence, risk factors, and outcome in a cohort of 241 patients. J Pediatr Hematol Oncol 2002; 24: 746-750.
12. Barker CC, Butzner JD, Anderson RA, et al. Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2003; 32: 79-87.
13. Cesaro S, Pillon M, Talenti E, et al. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Haematologica 2005; 90: 1396-1404.
14. Cheuk DK, Wang P, Lee TL, et al. Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 40: 935-944.
15. Essell JH, Schroeder MT, Harman GS, et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 975-981.
16. Ruutu T, Eriksson B, Remes K, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002; 100: 1977-1983.
17. Ohashi K, Tanabe J, Watanabe R, et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol 2000; 64: 32-38.
18. Goringe AP, Brown S, O'Callaghan U, et al. Glutamine and vitamin E in the treatment of hepatic veno-occlusive disease following high-dose chemotherapy. Bone Marrow Transplant 1998; 21: 829-832.
19. Takatsuka H, Takemoto Y, Iwata N, et al. Oral eicosapentaenoic acid for complications of bone marrow transplantation. Bone Marrow Transplant 2001; 28: 769-774.
20. Attal M, Huguet F, Rubie H, et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: A prospective, randomized trial. Blood 1992; 79: 2834-2840.
21. Forrest DL, Thompson K, Dorcas VG, et al. Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: A prospective phase II study. Bone Marrow Transplant 2003; 31: 1143-1149.
22. Dignan F, Gujral D, Ethell M, et al. Prophylactic defibrotide in allogeneic stem cell transplantation: Minimal morbidity and zero mortality from veno-occlusive disease. Bone Marrow Transplant 2007; 40: 79-82.
23. Meuleman DG, Hobbelen PM, van Dedem G, et al. A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: A survey of its pharmacological properties in experimental animal models. Thromb Res 1982; 27: 353-363.
24. Turpie AG, Levine MN, Hirsh J, et al. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet 1987; 1: 523-526.
25. Nieuwenhuis HK, Sixma JJ. Treatment of disseminated intravascular coagulation in acute promyelocytic leukemia with low molecular weight heparinoid Org 10172. Cancer 1986; 58: 761-764.
26. Harenberg J, Zimmermann R, Schwarz F, et al. Treatment of heparin-induced thrombocytopenia with thrombosis by new heparinoid. Lancet 1983; 1: 986-987.
27. Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 340S-380S.
28. Henny CP, Ten Cate H, Ten Cate JW, et al. Use of a new heparinoid as anticoagulant during acute haemodialysis of patients with bleeding complications. Lancet 1983; 1: 890-893.
29. Ibbotson T, Perry CM. Danaparoid: A review of its use in thromboembolic and coagulation disorders. Drugs 2002; 62: 2283-2314.
30. Harada N, Okajima K, Kohmura H, et al. Danaparoid sodium reduces ischemia/reperfusion-induced liver injury in rats by attenuating inflammatory responses. Thromb Haemost 2007; 97: 81-87.
31. Iba T, Miyasho T. Danaparoid sodium attenuates the increase in inflammatory cytokines and preserves organ function in endotoxemic rats. Crit Care 2008; 12: R86.
32. Hagiwara S, Iwasaka H, Hidaka S, et al. Danaparoid sodium inhibits systemic inflammation and prevents endotoxin-induced acute lung injury in rats. Crit Care 2008; 12: R43.